Molecular pathogenesis and progression of prostate cancer
about
Insights into Chemoresistance of Prostate CancerTenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceAndrogen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.Sortilin regulates progranulin action in castration-resistant prostate cancer cellsTenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinomaThe Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.Extracellular vesicles in prostate cancer: new future clinical strategies?Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Nonsteroidal anti-inflammatory drugs and prostatic diseasesTyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.On the relationship between tumor structure and complexity of the spatial distribution of cancer cell nuclei: a fractal geometrical model of prostate carcinoma.A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.TRPM4 regulates Akt/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerPositron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens.The context of prostate cancer genomics in personalized medicine.The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy.HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer.SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.Inhibition of human prostate cancer (PC-3) cells and targeting of PC-3-derived prostate cancer stem cells with koenimbin, a natural dietary compound from Murraya koenigii (L) Spreng.
P2860
Q26795589-F3095873-84F8-4D92-97D0-E766894271ECQ28543800-DE59607D-0E00-465E-8EAE-8E7FF6E06F40Q33621403-26C6444D-DD3D-4484-92AD-6851673B0C55Q33775723-C2D7C53B-D962-415A-8D83-692744FDB95CQ34375823-0B7E7C28-BE1D-45FF-8C83-4231915BA4D6Q34681161-2172E289-9E3B-4743-A82B-45019EB0C835Q34745270-C56F2653-0EFD-49BF-9CA0-0414559A9D77Q35423247-BC9CF649-8A2A-471A-805B-BEE3E121042AQ35921941-73BF3D4D-77DB-438F-B05C-7875DCEDCEA6Q36290399-174D7E0F-CE11-4738-9335-EA3805D821B8Q36568781-17D0324B-BCC2-40F5-850E-13DFE6C96F6AQ37632337-A628C1BE-39A7-447F-99BE-4D247C357B1AQ37673863-C9A0D547-8920-4978-9251-C12262E50436Q38203779-6DF296B4-211D-44D7-8277-6878F5BAF86AQ38217858-90BE6890-65C2-4381-960B-A850B73DE7BCQ38262816-EC633E01-AB0A-47D5-90D1-F99133AB9D2CQ38302346-924E62EE-6F5E-42C2-B045-2B5BC585B426Q38307367-5A8494F9-45DC-463C-A1C4-E22EEB508970Q38661520-77E76838-548C-4D41-A7DB-B983BAF2EF6BQ38671090-C2FEE814-BC69-435C-8EC9-0F9973A01D81Q38703676-EA2C39B5-5705-4843-9887-4CB71308D02CQ38765489-86832CB9-6112-4F4F-85FF-B2903C8D39F3Q38843958-D87FFCEF-4DD4-4591-9330-FDDE44D52533Q39164084-242EAB8C-6AEE-465E-BC1F-EC443F58BC27Q39242936-82AB68E5-AF92-4C05-9A8F-68CB12FC41D1Q39705804-0454FA0A-5D44-4E31-8452-DB02E1BA2F44Q40888865-B35410EC-AADD-4696-94B3-6846E012350DQ41701983-4F171BD0-E0C8-4A75-897A-5E2C13478BDCQ41839243-3CC5916A-D0C0-408C-8D19-1DDDCDF2897AQ42782654-6052F49E-EAF8-42FE-86A0-85EED1D79F81Q47876991-9AA86305-D5DA-44DF-98F9-9EBB39D8760BQ49813665-5413BBA3-2FF3-4F63-AD0A-AFEC5B504C69Q51395627-24B1F866-3025-40A4-BF31-1622A9466E74Q54088748-7C24C2A3-DA0B-4F1E-B3C1-36FB18B95E79
P2860
Molecular pathogenesis and progression of prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular pathogenesis and progression of prostate cancer
@en
Molecular pathogenesis and progression of prostate cancer.
@nl
type
label
Molecular pathogenesis and progression of prostate cancer
@en
Molecular pathogenesis and progression of prostate cancer.
@nl
prefLabel
Molecular pathogenesis and progression of prostate cancer
@en
Molecular pathogenesis and progression of prostate cancer.
@nl
P2860
P1433
P1476
Molecular pathogenesis and progression of prostate cancer
@en
P2093
Randy Schrecengost
P2860
P304
P356
10.1053/J.SEMINONCOL.2013.04.001
P577
2013-06-01T00:00:00Z